The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

It found that people on GLP-1 drugs like Wegovy and Ozempic reported eating fewer processed foods, red meat and sugary drinks ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...